Detalhe da pesquisa
1.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38385280
2.
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Eur J Haematol
; 112(3): 402-411, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37968873
3.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood
; 137(22): 3027-3036, 2021 06 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33739404
4.
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Br J Haematol
; 196(3): 639-648, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34671975
5.
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel.
Haematologica
; 107(11): 2536-2547, 2022 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35861017
6.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34496096
7.
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
Int J Mol Sci
; 23(24)2022 Dec 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36555520
8.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica
; 105(4): 1074-1080, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31248973
9.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31582542
10.
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
Am J Hematol
; 95(8): 900-905, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32282971
11.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Cancer
; 125(5): 750-760, 2019 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30561775
12.
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.
Haematologica
; 104(8): 1640-1647, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30733270
13.
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
Haematologica
; 103(9): 1422-1432, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30049825
14.
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.
Haematologica
; 103(11): 1772-1784, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30171031
15.
Elderly patients with multiple myeloma: towards a frailty approach?
Curr Opin Oncol
; 29(5): 315-321, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28763310
16.
How I treat fragile myeloma patients.
Blood
; 126(19): 2179-85, 2015 Nov 05.
Artigo
Inglês
| MEDLINE | ID: mdl-26324701
17.
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Blood
; 125(13): 2068-74, 2015 03 26.
Artigo
Inglês
| MEDLINE | ID: mdl-25628469
18.
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Eur J Haematol
; 98(3): 289-295, 2017 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-27893171
19.
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Am J Hematol
; 92(3): 244-250, 2017 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-28006855
20.
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Blood
; 124(1): 63-9, 2014 Jul 03.
Artigo
Inglês
| MEDLINE | ID: mdl-24855212